pharmaphorum4 年
Mission successful for Novartis after FDA approves ofatumumab in MS
Ofatumumab was first approved by the FDA as a cancer drug in chronic lymphocytic leukaemia (CLL), under the brand name Arzerra, in 2014 when it was owned by GlaxoSmithKline.
pharmaphorum5 天
FDA extends review of Novartis' MS drug ofatumumab
The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...